ter Veer, Emil
Ngai, Lok Lam
Valkenhoef, Gert van
Mohammad, Nadia Haj
Anderegg, Maarten C. J.
van Oijen, Martijn G. H.
van Laarhoven, Hanneke W. M.
Article History
Received: 26 January 2017
Accepted: 3 July 2017
First Online: 2 August 2017
Competing Interests
: Dr. Martijn G. H. van Oijen has received unrestricted research grants from Bayer, Lilly, Merck Serono, and Roche. Prof. Dr. Hanneke W. M. van Laarhoven has served as a consultant for Celgene, Lilly, and Nordic, and has received unrestricted research funding from Bayer, BMS, Celgene, Lilly, Merck Serono, MSD, Nordic, and Roche. Dr. Gert H. M. van Valkenhoef has served as a consultant for Johnson & Johnson. All other authors have no disclosures to report.